Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden

Fig. 2

Cost-effectiveness plane for the probabilistic sensitivity analysis. A Cost-effectiveness plane for the PSA for Norway. B Cost-effectiveness plane for the PSA for Sweden. Each point represents the ICER generated from one of 1,000 model iterations, which were run with the parameters randomly sampled from a distribution around the base case point estimate. Dashed line corresponds to a WTP threshold of €50,000/QALY. CE: cost-effectiveness; ICER: incremental cost-effectiveness ratio; PSA: probabilistic sensitivity analysis; QALY: quality-adjusted life year; WTP: willingness to pay

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us